BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Suissa S, Ernst P. Beta-Blockers in COPD: A Methodological Review of the Observational Studies. COPD 2018;15:520-5. [PMID: 30822238 DOI: 10.1080/15412555.2018.1554637] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Ruzieh M, Baugh AD, Al Jebbawi L, Edwards ES, Jia KQ, Dransfield MT, Foy AJ. Beta-blocker use in patients with chronic obstructive pulmonary disease: A systematic review: A systematic review of βB in COPD. Trends Cardiovasc Med 2021:S1050-1738(21)00139-0. [PMID: 34856338 DOI: 10.1016/j.tcm.2021.11.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Martin A, Hancox RJ, Chang CL, Beasley R, Wrobel J, McDonald V, Dobler CC, Yang IA, Farah CS, Cochrane B, Hillis GS, Scowcroft CP, Aggarwal A, Di Tanna GL, Balicki G, Galgey S, Jenkins C. Preventing adverse cardiac events (PACE) in chronic obstructive pulmonary disease (COPD): study protocol for a double-blind, placebo controlled, randomised controlled trial of bisoprolol in COPD. BMJ Open 2021;11:e053446. [PMID: 34452971 DOI: 10.1136/bmjopen-2021-053446] [Reference Citation Analysis]
3 Bakshi A, Suissa S. Effectiveness of Aspirin in COPD: Biases in the Observational Studies. COPD 2021;18:449-55. [PMID: 34396883 DOI: 10.1080/15412555.2021.1963696] [Reference Citation Analysis]
4 Leitao Filho FS, Choi L, Sin DD. Beta-blockers in chronic obstructive pulmonary disease: the good, the bad and the ugly. Curr Opin Pulm Med 2021;27:125-31. [PMID: 33332878 DOI: 10.1097/MCP.0000000000000748] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
5 Jiang S, Mohammadtursun N, Qiu J, Li Q, Sun J, Dong J. Recent advances on animal models related to chronic obstructive pulmonary disease. Tradit Med Mod Med 2019;02:93-104. [DOI: 10.1142/s2575900019300017] [Reference Citation Analysis]
6 Dransfield MT, Voelker H, Bhatt SP, Brenner K, Casaburi R, Come CE, Cooper JAD, Criner GJ, Curtis JL, Han MK, Hatipoğlu U, Helgeson ES, Jain VV, Kalhan R, Kaminsky D, Kaner R, Kunisaki KM, Lambert AA, Lammi MR, Lindberg S, Make BJ, Martinez FJ, McEvoy C, Panos RJ, Reed RM, Scanlon PD, Sciurba FC, Smith A, Sriram PS, Stringer WW, Weingarten JA, Wells JM, Westfall E, Lazarus SC, Connett JE; BLOCK COPD Trial Group. Metoprolol for the Prevention of Acute Exacerbations of COPD. N Engl J Med 2019;381:2304-14. [PMID: 31633896 DOI: 10.1056/NEJMoa1908142] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 17.3] [Reference Citation Analysis]
7 Alter P, Mayerhofer BA, Kahnert K, Watz H, Waschki B, Andreas S, Biertz F, Bals R, Vogelmeier CF, Jörres RA. Prevalence of cardiac comorbidities, and their underdetection and contribution to exertional symptoms in COPD: results from the COSYCONET cohort. Int J Chron Obstruct Pulmon Dis 2019;14:2163-72. [PMID: 31571852 DOI: 10.2147/COPD.S209343] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
8 Mersfelder TL, Shiltz DL. β-Blockers and the Rate of Chronic Obstructive Pulmonary Disease Exacerbations. Ann Pharmacother 2019;53:1249-58. [PMID: 31271049 DOI: 10.1177/1060028019862322] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]